ABSTRACT INTRODUCTION CURRENT CGM FEATURES RECENT CLINICAL EVIDENCE OF CGM IN PEOPLE WITH DIABETES BENEFITS OF CGM USE IN CLINICAL PRACTICE PRIORITY POPULATIONS FOR CGM IMPLEMENTATION CGM EXPANDABILITY: INTEGRATION WITH VARIOUS INSULIN DELIVERY DEVICES AND MOBILE APPLICATIONS ADVERSE EVENTS ASSOCIATED WITH CGM USE AND MANAGEMENT STRATEGIES IMPORTANCE OF STRUCTURED EDUCATION ON CGM SOCIO-ECONOMIC BURDEN OF CGM CONCLUSION Article information References ABSTRACT Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations
[56] This activation reduces the production of reactive oxygen species (ROS) and mitigates endoplasmic reticulum (ER) stress
10 Evidence suggests that berberine may improve lipid parameters, with 1 systematic review and meta-analysis finding reductions in total cholesterol, low-density lipoprotein cholesterol, and triglycerides
Preliminary evidence also points to two additional benefits: possible improvements in cognition and cardiovascular health
Semaglutide, manufactured by Novo Nordisk, belongs to a class of drugs called GLP-1 receptor agonists
Relapse rates for substance use disorders are comparable to those of chronic diseases like hypertension and diabetes, with estimates indicating that 40-60% of individuals may relapse during recovery
